Candel Therapeutics
CADL
71 hedge funds and large institutions have $156M invested in Candel Therapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 2 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 2
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
236% more capital invested
Capital invested by funds: $46.4M → $156M (+$109M)
103% more call options, than puts
Call options by funds: $9.79M | Put options by funds: $4.83M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
37% more funds holding
Funds holding: 52 → 71 (+19)
21.4% more ownership
Funds ownership: 20.86% → 42.26% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$17.6M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$9.45M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.45M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$108K |
| 2 |
AI
Atom Investors
Austin,
Texas
|
-$103K |
| 3 |
Jane Street
New York
|
-$95.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$20.1K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
-$17.7K |
CADL Hedge Fund Activity: Q4 2024 in Review
71 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q4 2024, worth a combined $156M — up 236% from $46.4M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CADL positions and 2 closed out — a net gain of 20 holders — while 33 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.1M. The largest seller was Simplex Trading, cutting an estimated $108K.
- 71 institutional investors held Candel Therapeutics (CADL) as of Q4 2024, up from 52 in Q3 2024.
- Funds reported $156M of Candel Therapeutics stock for Q4 2024, up 236% quarter-over-quarter.
- 22 funds opened new Candel Therapeutics positions in Q4 2024 and 2 closed out, a net change of +20 holders.
- The largest Candel Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $23.1M added.
- The largest Candel Therapeutics seller in Q4 2024 was Simplex Trading, an estimated $108K sold.
Based on aggregated 13F filings for Q4 2024.